Independent Investment Manager Sells $24.6 Million of Exponent Stock, According to Recent Filing

Conestoga Capital Advisors, LLC disclosed an SEC filing on October 24, 2025, detailing the sale of 344,631 shares of Exponent (NASDAQ:EXPO) in Q3 2025, valued at an estimated $24.63 million. Following this partial divestment, Conestoga retains 2,361,196 shares worth $164.06 million, with Exponent now comprising 2.63% of the fund's AUM, down from 2.99%. This reduction in exposure comes as Exponent shares have significantly underperformed the S&P 500, falling 35.61% year-to-date while the benchmark advanced, signaling a potential re-evaluation of the position by the fund.

Analysis

Conestoga Capital Advisors, LLC, executed a partial sale of 344,631 shares of Exponent (NASDAQ:EXPO) in Q3 2025, valued at an estimated $24.63 million. This transaction reduced Exponent's weighting in the fund's AUM from 2.99% to 2.63%. Despite the sale, Conestoga retains a significant position of 2,361,196 shares, worth $164.06 million, indicating continued, albeit reduced, conviction.

The divestment follows a period of severe underperformance for EXPO, with shares down 35.61% year-to-date as of October 23, 2025, significantly trailing the S&P 500 by 50.09 percentage points. This underperformance extends over a three-year period, where EXPO has lagged the S&P 500 by over 100 percentage points. The fund's decision to trim its stake, despite not being a full exit, suggests a re-evaluation of the stock's prospects amidst persistent weakness.

While the sale represents a 13% reduction in Conestoga's EXPO holding, the stock remains the fund's 11th largest position, implying that fund managers still hold some confidence in the company. Exponent's business model as a multidisciplinary consulting service provider with a diversified client base and fee-for-service structure remains intact. However, the timing of the sale, coupled with the stock's poor market performance, presents a mixed signal for investors.

Key Decisions for Investors

• Investors should acknowledge the moderately negative signal from Conestoga's partial divestment, particularly given Exponent's significant and prolonged underperformance against the S&P 500.
• Given the mixed signals—a partial sale versus a retained top holding—investors should avoid immediate, reactive decisions and instead conduct thorough fundamental analysis on Exponent's business outlook.
• Monitor future institutional filings and Exponent's upcoming earnings reports for clearer directional signals, especially concerning any potential catalysts for improved market performance.